• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Kings College London - Articles and news items

stem-cells-rdeb

Trial of new stem cell therapy for dystrophic epidermolysis bullosa (RDEB) gives promising results

Industry news / 1 June 2015 /

Results from a trial of a new stem-cell based therapy for a rare skin condition, recessive dystrophic epidermolysis bullosa (RDEB), have been published…

Sigma Life Sciences logo

Sigma® Life Science and King’s College London co-developing miRNA Target Identification Technology

News, Supplier news / 5 May 2011 / kdm communications limited

Exclusive license to develop and commercialize new technology…

Stem Cells Roundtable

Issue 2 2009, Past issues / 20 March 2009 /

1. What do you feel are the current changing attitudes to Stem Cell Research?

Paul Andrews: First of all are we talking throughout this roundtable about human stem cells? Are we differentiating between human embryonic stem cells and adult stem cells, or patient-derived induced pluripotent stem (iPS) cells? The differences in attitude and responses could be completely different. In addition: what do we mean by research: research aimed at therapy; for drug testing that might reduce reliance on animal models and lead to better drug safety; or basic cell biology research?

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +